A rat study found Zuogui Wan improved sperm quality partly by reducing testicular copper accumulation and suppressing cuproptosis
Journal: Journal of Ethnopharmacology | Published: 2025-12-13 | Type: Animal Study | PMID: 41397546 Authors: Zha Yarong, Li Hongwei, Jiang Shan, Wang Zhuo, Liu Yang, Wei Zhitao, Yang Yong — all Changchun University of Chinese Medicine, Department of Urology Funding/COI: Funding not listed. COI statement is boilerplate and ambiguous; reads as a standard declaration rather than a substantive disclosure. No industry relationships declared.
Zuogui Wan (ZGW) is a Ming Dynasty TCM formula used for male infertility. This study used RNA-Seq in a chemically induced rat model to identify how ZGW might work mechanistically, focusing on oxidative stress, mitochondrial function, apoptosis, and a newly described cell death pathway called cuproptosis — copper-mediated mitochondrial protein aggregation. ZGW treatment reduced testicular copper content and downregulated key cuproptosis proteins, while also improving oxidative stress markers and sperm nuclear integrity. Everything here is in rats.
This is an animal study, full stop. The model is GTW (Tripterygium wilfordii glycosides)-induced oligoasthenozoospermia in 66 male Sprague-Dawley rats divided into six groups — roughly 11 per group. The GTW model is widely used in TCM male infertility research but is chemically induced and does not reflect the polygenic and multifactorial etiology of human oligoasthenozoospermia. The study's strongest feature is methodological breadth: RNA-Seq with functional enrichment is paired with five independent validation methods (qPCR, Western blot, IHC, immunofluorescence, copper content assay). That said, the abstract provides no actual numbers — no sperm concentration means, no motility percentages, no p-values, no effect sizes. For a paper whose claims rest on quantitative molecular biology, that omission is notable.
Cuproptosis was first described as a distinct cell death mechanism in 2022; applying it to male infertility is genuinely novel framing. Whether the pathway is clinically relevant to human sperm production is entirely unknown.
This is hypothesis-generating rat pharmacology, not evidence of clinical efficacy. The cuproptosis angle is scientifically interesting — it's a real and recently characterized cell death pathway, and the idea that copper dysregulation in the testes impairs spermatogenesis is plausible. But 66 rats, no human data, missing effect sizes, and a kitchen-sink multi-pathway design mean this paper earns curiosity, not confidence. File it under "interesting mechanistic lead, needs replication with rigorous controls and, eventually, humans."